Literature DB >> 23529214

Reference ranges and cutoff levels of pneumococcal antibody global serum assays (IgG and IgG2) and specific antibodies in healthy children and adults.

M A Rose1, J Buess, Y Ventur, S Zielen, E Herrmann, J Schulze, R Schubert.   

Abstract

Pneumococcal antibodies represent the acquisition of natural immunity. Determination of pneumococcal antibodies is an important screening tool for immunodeficiencies. Our study generated reference ranges and cutoff levels for pneumococcal antibody global serum assays correlated to a specific pneumococcal antibody ELISA. Specific pneumococcal antibody levels were measured from 457 children undergoing elective surgery and 46 healthy adult volunteers (88 with previous pneumococcal immunization from both groups), 22 severe immunodeficient subjects with ataxia telangiectasia (A-T, negative controls), and age-matched 36 healthy allergic asthmatics. We determined a representative panel of serotype-specific pneumococcal antibodies (serotype 4, 5, 6B, 7F, 14, 18C, 19F, 23F) by ELISA and global pneumococcal IgG and IgG2 antibodies by EIA. In vaccine-naïve healthy subjects, initial pneumococcal IgG geometric mean concentrations of 13.1 μg/ml were low in the first year of life and increased over the time, reaching adult levels (70.5 μg/ml) at age 8-12 years. In parallel, IgG2 antibodies increased from 20.7 % (0.5-1 year old) to adult proportions (>30 %) in preschoolers. Correlation between the pneumococcal IgG screening assay and specific pneumococcal antibody levels was acceptable (Pearson's coefficient r = 0.4455; p = 0.001). Cutoff levels showed high sensitivity, whereas specificity was high to moderate calculated from correlations with the specific ELISA. We provide reference ranges and cutoff levels for the interpretation of specific antibody determinations in the clinical setting. The global pneumococcal IgG/IgG2 assay is a suitable screening tool and correlates with the ELISA serotype-specific pneumococcal antibodies. However, results below our cutoff values should be re-evaluated by serotype-specific ELISA testing.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23529214     DOI: 10.1007/s00430-013-0292-3

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  26 in total

1.  Interlaboratory reproducibility of an enzyme-linked immunosorbent assay for quantitation of antibodies for Haemophilus influenzae type b polysaccharide.

Authors:  D V Madore; S A Quataert
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

2.  Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs.

Authors:  A F Ochsenbein; D D Pinschewer; S Sierro; E Horvath; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

3.  Patient-centred screening for primary immunodeficiency: a multi-stage diagnostic protocol designed for non-immunologists.

Authors:  E de Vries
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

4.  Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay.

Authors:  N F Concepcion; C E Frasch
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

5.  Levels of antibodies specific to tetanus toxoid, Haemophilus influenzae type b, and pneumococcal capsular polysaccharide in healthy children and adults.

Authors:  Uwe Schauer; Frank Stemberg; Christian H L Rieger; Wolfgang Büttner; Michael Borte; Simone Schubert; Helga Möllers; Frank Riedel; Udo Herz; Harald Renz; Wilhelm Herzog
Journal:  Clin Diagn Lab Immunol       Date:  2003-03

6.  Does the 23-valent pneumococcal vaccine protect cochlear implant recipients?

Authors:  Christiane Hey; Markus A Rose; Sandy Kujumdshiev; Wolfgang Gstoettner; Ralf Schubert; Stefan Zielen
Journal:  Laryngoscope       Date:  2005-09       Impact factor: 3.325

7.  IgG subclasses and avidity of antibodies to polysaccharide antigens in allogeneic BMT recipients after vaccination with pneumococcal polysaccharide and Haemophilus influenzae type b conjugate vaccines.

Authors:  T Parkkali; H Käyhty; M Anttila; T Ruutu; T Wuorimaa; A Soininen; L Volin; P Ruutu
Journal:  Bone Marrow Transplant       Date:  1999-09       Impact factor: 5.483

8.  Measurement and interpretation of pneumococcal IgG levels for clinical management.

Authors:  P Balmer; J North; D Baxter; E Stanford; A Melegaro; E B Kaczmarski; E Miller; R Borrow
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

9.  Impaired pneumococcal immunity in children after treatment for acute lymphoblastic leukaemia.

Authors:  Thomas Lehrnbecher; Ralf Schubert; Michael Behl; Melanie Koenig; Markus A Rose; Ulrike Koehl; Roland Meisel; Hans-Jürgen Laws
Journal:  Br J Haematol       Date:  2009-09-18       Impact factor: 6.998

10.  Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.

Authors:  George R Siber; Ih Chang; Sherryl Baker; Philip Fernsten; Katherine L O'Brien; Mathuram Santosham; Keith P Klugman; Shabir A Madhi; Peter Paradiso; Robert Kohberger
Journal:  Vaccine       Date:  2007-02-21       Impact factor: 3.641

View more
  5 in total

Review 1.  Vaccination against infectious diseases: what is promising?

Authors:  Hans Wilhelm Doerr; Annemarie Berger
Journal:  Med Microbiol Immunol       Date:  2014-07-27       Impact factor: 3.402

Review 2.  A critical review of perfluorooctanoate and perfluorooctanesulfonate exposure and immunological health conditions in humans.

Authors:  Ellen T Chang; Hans-Olov Adami; Paolo Boffetta; H James Wedner; Jack S Mandel
Journal:  Crit Rev Toxicol       Date:  2016-01-13       Impact factor: 5.635

3.  Value of the Overall Pneumococcal Polysaccharide Response in the Diagnosis of Primary Humoral Immunodeficiencies.

Authors:  Benjamin Lopez; Mathilde Bahuaud; Claire Fieschi; Souad Mehlal; Mohamed Jeljeli; Stéphanie Rogeau; Séverine Brabant; Anne-Sophie Deleplancque; Sylvain Dubucquoi; Sandrine Poizot; Louis Terriou; David Launay; Frédéric Batteux; Myriam Labalette; Guillaume Lefèvre
Journal:  Front Immunol       Date:  2017-12-20       Impact factor: 7.561

4.  Response to pneumococcal vaccination in multiple myeloma.

Authors:  Loïc Renaud; Susanna Schraen; Guillemette Fouquet; Stephanie Guidez; Hélène Demarquette; Morgane Nudel; Emilie Cayssials; Claire Bories; Charles Herbaux; Thomas Systchenko; Jean-Luc Faucompré; Antoine Machet; Florence Sabirou; Antony Levy; Arthur Bobin; Valentine Richez; Niels Moya; Cécile Gruchet; Deborah Desmier; Zoe van de Wyngaert; Benjamin Carpentier; Salomon Manier; Thierry Facon; Stephen Harding; Xavier Leleu
Journal:  Cancer Med       Date:  2019-05-30       Impact factor: 4.452

5.  Focusing on Good Responders to Pneumococcal Polysaccharide Vaccination in General Hospital Patients Suspected for Immunodeficiency. A Decision Tree Based on the 23-Valent Pneumococcal IgG Assay.

Authors:  Lisanne M A Janssen; Michiel Heron; Jean-Luc Murk; Alexander C A P Leenders; Ger T Rijkers; Esther de Vries
Journal:  Front Immunol       Date:  2019-11-05       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.